Nevro has filed to list public shares on the NYSE under the symbol NVRO, hoping to raise up to $115 million in an IPO. The medical device company increased its revenue to $23.5 million in the year ended December 31, 2013—up from $18.2 million the year prior—with a net loss of $26 million. Nevro will use proceeds from its IPO to continue efforts towards U.S. regulatory approval and commercial launch of a pain-relief system. Its most recent fundraise happened in early 2013, when it brought in $48 million at a valuation north of $233 million. Investors include Bay City Capital (13.4% pre-IPO stake), Three Arch Partners (13.4%) and Novo A/S (12%), among others.